ZYME (Zymeworks Corp) Utang jangka dawa

Strategic risks for Zymeworks Inc. (ZYME) are linked to an inflated rate for a single drug and research costs, with the indicator standing at 0.28. Zymeworks Inc. (ZYME) is developing multispecific antibodies, relying on the support of major partners to advance zanidatamab. This price chart reflects the asset's dynamics, whose resilience is based on technology licensing and the diversification of oncology projects to secure stable royalties.

ZYME (Zymeworks Corp) riwayat Utang jangka dawa perusahaan saka 04.07.2022 nganti 28.10.2026

Rincian metrik keuangan lan pasar Zymeworks Corp (ZYME)

- rega lan prakiraan konsensus rega:

Kutipan saham zymeworks.com|ZYME - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Zymeworks|ZYME - Nilai Total Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Zymeworks|ZYME - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku zymeworks.com|ZYME - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Utang marang Modal Zymeworks Inc.|ZYME - Rasio utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal Zymeworks Biopharmaceuticals|ZYME - Gunggung utang perusahaan|Rasio utang marang aset resik Zymeworks|ZYME - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Zymeworks

Analisis komprehensif perusahaan:ZYME (zymeworks.com)

Long-term debt aggregates loan and bond obligations with maturities exceeding one year, allowing for an assessment of the debt load and the cost of borrowed capital. By analyzing the value of the firm's long-term borrowings, an investor determines the financial stability of Zymeworks Inc. (ZYME), which is bolstered by the cyclical independence of cancer immunotherapy and stable demand for treatment regardless of market turmoil.

Perusahaan pesaing